[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported a grant vesting on 08/15/2025 that resulted in the acquisition of 69 shares of common stock at no cash price. After the reported transaction Potter beneficially owns 18,265 shares. The filing lists the underlying award as Restricted Stock Units that vested in part earlier: 25% vested on October 15, 2022, with the remaining 75% scheduled to vest in substantially equal monthly installments over the following three years. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Insights

Financial Analyst

TL;DR: Routine director RSU vesting; small issuance relative to total holdings, limited near-term market impact.

The Form 4 documents a non-cash acquisition of 69 shares via Restricted Stock Units vesting on 08/15/2025, increasing Myrtle Potter's beneficial ownership to 18,265 shares. This appears to be scheduled compensation rather than a discretionary market purchase or sale. From a financial perspective, the size of the award is modest relative to typical director holdings and is unlikely to materially affect GH's share count or liquidity. The disclosed vesting schedule confirms these were time-based awards with earlier partial vesting on 10/15/2022 and monthly vesting thereafter for three years.

Corporate Governance Expert

TL;DR: Standard equity compensation disclosure showing alignment incentives; no governance red flags in the filing.

The report shows a director receiving 69 shares through RSU vesting at $0 purchase price, a common mechanism to align board members with shareholder interests. The disclosure includes the vesting schedule and signer information (attorney-in-fact), meeting SEC Form 4 requirements. There are no indications of related-party transactions, option repricing, or unusual timing that would raise governance concerns based solely on this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POTTER MYRTLE S

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		69	A	$0	18,265	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	08/15/2025		M			69	(1)	(2)	Common Stock	69	$0	137	D

Explanation of Responses:

1. The restricted stock unit vested 25% of the shares subject to such award on October 15, 2022. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.